THAR Key Statistics, Chart & Performance
The current stock price of THAR is 2.79 USD. In the past month the price increased by 3.72%. In the past year, price increased by 36.1%.
THAR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About THAR
Company Profile
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Company Info
THARIMMUNE INC
1200 Route 22 East
Bridgewater NEW JERSEY US
Employees: 2
Phone: 13027432995
THARIMMUNE INC / THAR FAQ
Can you describe the business of THARIMMUNE INC?
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
What is the stock price of THARIMMUNE INC today?
The current stock price of THAR is 2.79 USD. The price decreased by -4.12% in the last trading session.
What is the dividend status of THARIMMUNE INC?
THAR does not pay a dividend.
What is the ChartMill rating of THARIMMUNE INC stock?
THAR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for THAR stock?
THARIMMUNE INC (THAR) currently has 2 employees.
THAR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to THAR. When comparing the yearly performance of all stocks, THAR is one of the better performing stocks in the market, outperforming 72.41% of all stocks.
THAR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to THAR. THAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
THAR Financial Highlights
Over the last trailing twelve months THAR reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS increased by 77.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.03% | ||
| ROE | -167.66% | ||
| Debt/Equity | 0.03 |
THAR Forecast & Estimates
7 analysts have analysed THAR and the average price target is 5.1 USD. This implies a price increase of 82.8% is expected in the next year compared to the current price of 2.79.